Scicinib

赛西尼

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameScicinib
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRibonucleotide reductase inhibitors
TargetsRibonucleotide reductase
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesSuzhou Cheers Pharmaceutical Co LtdKananji Medicine Technology (Shanghai) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesKananji Medicine Technology (Shanghai) Co LtdSuzhou Cheers Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungHematologic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A